Company Announcements
Results for First Quarter Ended 30 September 2017
By LSE RNS
14 November 2017
BEXIMCO PHARMACEUTICALS LTD.
Financial Results for the First Quarter Ended 30 September 2017
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces its unaudited results for the three month period ended 30 September 2017. The information set out below has been released to the Dhaka and Chittagong Stock Exchanges in compliance with the requirements from the Bangladesh SEC.
The detail accounts can be viewed at the Company website: www.beximco-pharma.com
For further information please visit www.beximco-pharma.com or enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, ext.20080
Md. Asad Ullah, FCS, Executive Director & Company Secretary
Tel; +880 2 58611891, +880 2 58612040, Ext 10140
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555
Northland Capital Partners Limited (Broker)
Gerry Beaney / Tom Price
Tel: +44 (0)20 3861 6625
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. Ensuring access to quality medicines is the powerful aspiration that motivates 3,500 employees of the Company.
Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in South East Asia, including Singapore, Thailand, Taiwan, Malaysia, Indonesia, Philippines and Hong Kong; Africa, including South Africa, Mauritius, Kenya, Ghana, Ethiopia, Uganda and Nigeria; Central Asia, including Azerbaijan; Middle East, including Kuwait and Jordan; Pacific Island countries; Latin and Central American countries; Europe, including Austria, Germany and Romania; Australia and North America, including the USA and Canada.
Beximco Pharmaceuticals Limited
Statement of Financial Position (Un-audited)
As at 30 September 2017
|
|
|
|
|
Taka '000 |
|
|
|
As at 30 September 2017 |
|
As at 30 June 2017 |
|
ASSESTS |
|
|
|
|
|
Non-Current Assets |
|
25,425,973 |
|
24,953,317 |
|
Property, Plant and Equipment- Carrying Value |
|
24,905,140 |
|
24,472,468 |
|
Intangible Assets |
|
503,323 |
|
462,969 |
|
Investment in Shares |
|
17,510 |
|
17,880 |
|
|
|
|
|
|
|
Current Assets |
|
9,042,705 |
|
9,130,816 |
|
Inventories |
|
3,645,626 |
|
3,468,089 |
|
Spares & Supplies |
|
635,638 |
|
636,103 |
|
Accounts Receivable |
|
2,170,303 |
|
2,167,340 |
|
Loans, Advances and Deposits |
|
1,783,584 |
|
1,697,679 |
|
Short Term Investment |
|
611,992 |
|
886,577 |
|
Cash and Cash Equivalents |
|
195,562 |
|
275,028 |
|
|
|
|
|
|
|
TOTAL ASSETS |
|
34,468,678 |
|
34,084,133 |
|
|
|
|
|
|
|
EQUITY AND LIABILITIES |
|
|
|
|
|
Shareholders' Equity |
|
25,694,062 |
|
25,072,426 |
|
Issued Share Capital |
|
4,055,564 |
|
4,055,564 |
|
Share Premium |
|
5,269,475 |
|
5,269,475 |
|
Excess of Issue Price over Face Value of GDRs |
|
1,689,637 |
|
1,689,637 |
|
Capital Reserve on Merger |
|
294,951 |
|
294,951 |
|
Revaluation Surplus |
|
1,165,118 |
|
1,190,204 |
|
Unrealised Gain/(Loss) |
|
3,505 |
|
3,875 |
|
Retained Earnings |
|
13,215,812 |
|
12,568,720 |
|
|
|
|
|
|
|
Non-Current Liabilities |
|
5,698,801 |
|
5,605,667 |
|
Long Term Borrowings-Net off Current Maturity (Secured) |
|
2,700,192 |
|
2,635,907 |
|
Liability for Gratuity and WPPF & Welfare Funds |
|
1,137,581 |
|
1,117,094 |
|
Deferred Tax Liability |
|
1,861,028 |
|
1,852,666 |
|
|
|
|
|
|
|
Current Liabilities and Provisions |
|
3,075,815 |
|
3,406,040 |
|
Short Term Borrowings (Secured) |
|
812,700 |
|
1,239,758 |
|
Long Term Borrowings-Current Maturity (Secured) |
|
772,162 |
|
715,790 |
|
Creditors and Other Payables |
|
752,120 |
|
783,839 |
|
Accrued Expenses |
|
264,204 |
|
245,375 |
|
Dividend Payable |
|
353 |
|
353 |
|
Income Tax Payable |
|
474,276 |
|
420,925 |
|
|
|
|
|
|
|
TOTAL EQUITY AND LIABILITIES |
|
34,468,678 |
|
34,084,133 |
Beximco Pharmaceuticals Limited
Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the first quarter ended 30 September 2017
|
|
|
|
|
Taka '000 |
|
|
|
|
July - September 2017 |
|
July - September 2016 |
|
|
|
|
|
|
|
|
|
Net Sales Revenue |
|
4,278,675 |
|
3,765,598 |
|
|
Cost of Goods Sold |
|
(2,304,485) |
|
(2,034,055) |
|
|
|
|
|
|
|
|
|
Gross Profit |
|
1,974,190 |
|
1,731,543 |
|
|
|
|
|
|
|
|
|
Operating Expenses |
|
(1,015,776) |
|
(867,964) |
|
|
Administrative Expenses |
|
(143,511) |
|
(130,589) |
|
|
Selling, Marketing and Distribution Expenses |
|
(872,265) |
|
(737,375) |
|
|
|
|
|
|
|
|
|
Profit from Operations |
|
958,414 |
|
863,579 |
|
|
|
|
|
|
|
|
|
Other Income |
|
22,411 |
|
44,374 |
|
|
Finance Cost |
|
(106,170) |
|
(162,767) |
|
|
Profit Before Contribution to WPPF & Welfare Funds |
|
874,655 |
|
745,186 |
|
|
|
|
|
|
|
|
|
Contribution to WPPF & Welfare Funds |
|
(41,650) |
|
(35,485) |
|
|
|
|
|
|
|
|
|
Profit Before Tax |
|
833,005 |
|
709,701 |
|
|
|
|
|
|
|
|
|
Income Tax Expenses |
|
(188,509) |
|
(194,751) |
|
|
Current Tax |
|
(202,637) |
|
(164,999) |
|
|
Deferred Tax |
|
14,128 |
|
(29,752) |
|
|
|
|
|
|
|
|
|
Profit After Tax |
|
644,496 |
|
514,950 |
|
|
Other Comprehensive Income-Unrealised Gain/(Loss) |
|
(370) |
|
(93) |
|
|
|
|
|
|
|
|
|
Total Comprehensive Income |
|
644,126 |
|
514,857 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings Per Share (EPS) / Adjusted EPS |
Tk. |
1.59 |
|
1.27 |
|
|
Number of Shares used to compute EPS |
Nos. |
405,556,445 |
|
405,556,445 |
|
Beximco Pharmaceuticals Limited
Statement of Changes in Equity (Un-audited)
For the first quarter ended 30 September 2017
|
As at 30 September 2017 |
Taka '000 |
|||||||||||
|
|
Share Capital |
Share Premium |
Excess of Issue Price over Face Value of GDRs |
Capital Reserve on Merger |
Revaluation Surplus |
Un-realised Gain / (Loss) |
Retained Earnings |
Total |
||||
|
Balance as on 1 July 2017 |
4,055,564 |
5,269,475 |
1,689,637 |
294,951 |
1,190,204 |
3,875 |
12,568,720 |
25,072,426 |
||||
|
Total Comprehensive Income for the period: |
|
|
|
|
|
|
|
|
||||
|
Profit for the Period |
- |
- |
- |
- |
- |
- |
644,496 |
644,496 |
||||
|
Other Comprehensive Income / (Loss) |
- |
- |
- |
- |
- |
(370) |
- |
(370) |
||||
|
Adjustment for Depreciation on Revalued Assets |
- |
- |
- |
- |
(2,596) |
- |
2,596 |
- |
||||
|
Adjustment for Deferred Tax on Revalued Assets |
- |
- |
- |
- |
(22,490) |
- |
- |
(22,490) |
||||
|
Balance as on 30 September 2017 |
4,055,564 |
5,269,475 |
1,689,637 |
294,951 |
1,165,118 |
3,505 |
13,215,812 |
25,694,062 |
||||
|
|
|
|
|
|
|
|
|
|
||||
|
Number of Shares on 30 September 2017 |
|
|
|
|
|
|
|
405,556,445 |
||||
|
Net Asset Value (NAV) Per Share on 30 September 2017 |
|
|
|
|
|
|
Tk. |
63.36 |
||||
|
As at 30 September 2016 |
Taka '000 |
|||||||||||
|
|
Share Capital |
Share Premium |
Excess of Issue Price over Face Value of GDRs |
Capital Reserve on Merger |
Revaluation Surplus |
Un-realised Gain / (Loss) |
Retained Earnings |
Total |
||||
|
Balance as on 1 July 2016 |
3,862,442 |
5,269,475 |
1,689,637 |
294,951 |
1,225,100 |
1,295 |
10,716,512 |
23,059,412 |
||||
|
Total Comprehensive Income for the period: |
|
|
|
|
|
|
|
|
||||
|
Profit for the Period |
- |
- |
- |
- |
- |
- |
514,950 |
514,950 |
||||
|
Other Comprehensive Income / (Loss) |
- |
- |
- |
- |
- |
(93) |
- |
(93) |
||||
|
Adjustment for Depreciation on Revalued Assets |
- |
- |
- |
- |
(2,939) |
- |
2,939 |
- |
||||
|
Adjustment for Deferred Tax on Revalued Assets |
- |
- |
- |
- |
(25,343) |
- |
- |
(25,343) |
||||
|
Balance as on 30 September 2016 |
3,862,442 |
5,269,475 |
1,689,637 |
294,951 |
1,196,818 |
1,202 |
11,234,401 |
23,548,926 |
||||
|
|
|
|
|
|
|
|
|
|
||||
|
Number of Shares on 30 September 2016 |
|
|
|
|
|
|
|
386,244,234 |
||||
|
Net Asset Value (NAV) Per Share on 30 September 2016 |
|
|
|
|
|
|
Tk. |
60.97 |
||||
Beximco Pharmaceuticals Limited
Statement of Cash Flows (Un-audited)
For the first quarter ended 30 September 2017
|
|
|
|
|
Taka '000 |
|
|
|
|
July - September 2017 |
|
July - September 2016 |
|
|
|
|
|
|
|
|
|
Cash Flows from Operating Activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Receipts from Customers and Others |
|
4,278,700 |
|
3,614,145 |
|
|
Payments to Suppliers and Employees |
|
(3,414,603) |
|
(2,747,221) |
|
|
Cash Generated from Operations |
|
864,097 |
|
866,924 |
|
|
|
|
|
|
|
|
|
Interest Paid |
|
(106,170) |
|
(162,767) |
|
|
Interest Received |
|
25,636 |
|
43,386 |
|
|
Income Tax Paid |
|
(149,286) |
|
(122,735) |
|
|
Net Cash Generated from Operating Activities |
|
634,277 |
|
624,808 |
|
|
|
|
|
|
|
|
|
Cash Flows from Investing Activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquisition of Property, Plant and Equipment |
|
(626,542) |
|
(289,899) |
|
|
Intangible Assets |
|
(49,457) |
|
(14,496) |
|
|
Disposal of Property, Plant and Equipment |
|
571 |
|
1,166 |
|
|
Decrease in Short Term Investment |
|
274,585 |
|
68,808 |
|
|
Net Cash Used in Investing Activities |
|
(400,843) |
|
(234,421) |
|
|
|
|
|
|
|
|
|
Cash Flows from Financing Activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Increase/(Decrease) in Long Term Borrowings |
|
114,158 |
|
(187,698) |
|
|
Net Increase/(Decrease) in Short Term Borrowings |
|
(427,058) |
|
(151,091) |
|
|
Net Cash Generated from Financing Activities |
|
(312,900) |
|
(338,789) |
|
|
Increase / (Decrease) in Cash and Cash Equivalents |
|
(79,466) |
|
51,598 |
|
|
Cash and Cash Equivalents at Beginning of Period |
|
275,028 |
|
221,121 |
|
|
Cash and Cash Equivalents at End of Period |
|
195,562 |
|
272,719 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Operating Cash Flow Per Share |
Tk. |
1.56 |
|
1.62 |
|
|
Number of Shares used to compute Net Operating Cash Flow Per Share |
|
405,556,445 |
|
386,244,234 |
|
This information is provided by RNS
You are here: news > regulatory news
10 Lower Thames St,
London EC3R 6EN